Categories: News

Comment on the interview for the journal Dienas Bizness

Comment on the interview for the journal Dienas Bizness

The Management Board of  “Olainfarm” got acquainted with the interview with Roberts Tavjevs, Member of the Board of the largest shareholder AS “AB CITY”, who controls 50.93% of the company’s voting capital, for the journal Dienas Bizness, which provides information on future plans for “Olainfarm”, including the perspective of profit distribution, namely, that no dividends are planned to be paid in the next five years.

The Management Board of “Olainfarm” informs that the above-mentioned is contrary to the dividend policy approved by the Council of “Olainfarm”. At the same time, it should be noted that only the shareholders’ meeting has the right to decide on the amount of dividends to be paid to “Olainfarm” shareholders.

Changes to the dividend policy, if necessary, shall be prepared by the Management Board and submitted to the Council for approval when necessary.

Additional information:  
Jānis Leimanis
JSC Olainfarm Member of Management Board
Phone: +371 29269424
Email: janis.leimanis@olainfarm.com

Staff

Recent Posts

Christopher Barnett, Founder & CEO of ABA Centers, Named Entrepreneur Of The Year 2024 Florida Winner by EY

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- This weekend, Ernst & Young LLP (EY US)…

5 hours ago

Healthee Unveils AI-Driven Enhanced Plan Comparison Tool, Setting a New Standard in Innovative Technology for Streamlining Open Enrollment

Improved tool maximizes decision support for employees, simplifying the annual open enrollment process for organizations.…

5 hours ago

Anju Showcases Advanced eClinical Suite at DIA Global Annual Meeting 2024

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- Anju Software, a trailblazer in comprehensive data…

5 hours ago

EHEALTH TECHNOLOGIES PARTNERS WITH CANCERX AND WHITE HOUSE CANCER MOONSHOT

PITTSBURGH, June 17, 2024 /PRNewswire/ -- eHealth Technologies -- a leading healthcare technology company that…

5 hours ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results

Revenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in…

5 hours ago